Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind (Except Moxifloxacin), Placebo and Positive-Controlled, Four-Period Crossover Thorough QT/QTc Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants

NCT07708272 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07708272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07708272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind (Except Moxifloxacin), Placebo and Positive-Controlled, Four-Period Crossover Thorough QT/QTc Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 30, 2026
Completion date
February 28, 2027
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis